- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
ANCHORAGE, Alaska, June 9, 2026 /CNW/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to provide an update on the...
BAKU, Azerbaijan, June 9, 2026 /PRNewswire/ -- Aztelekom, a part of AZCON Holding company, and Huawei announced today that the nation's "Online Azerbaijan" broadband...
DUBAI, UAE, June 9, 2026 /PRNewswire/ -- XRP Healthcare, the first AI healthcare platform built on the XRP Ledger, today announced continued growth across...
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program tosupport advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease
New Games Launch as Part of Hellenic Lotteries' New Concession of Greek State LotteriesATLANTA, June 9, 2026 /PRNewswire/ -- Scientific Games, the world's largest lottery...